English
Regional settings| Spread | 0.13 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 22.48 |
| Open | 22.41 |
| 1-Year Change | 25.34% |
| Day's Range | 22.29 - 22.41 |
Rocket Pharmaceuticals, Inc. is a clinical-stage, multi-platform biotechnology company that is focused on the development of gene therapies for rare and devastating diseases. The Company’s clinical-stage ex vivo lentiviral vector (LVV) programs include: Fanconi Anemia (FA), is a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; Leukocyte Adhesion Deficiency-I (LAD-I), is a genetic disorder that causes the immune system to malfunction; Pyruvate Kinase Deficiency (PKD), is a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia, and Infantile Malignant Osteopetrosis (IMO), is a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption.
BRIEF: For the fiscal year ended 31 December 2021, Rocket Pharmaceuticals Inc revenues was not reported. Net loss increased 21% to $169.1M. Higher net loss reflects research and development expense balanci increase of 15% to $113.5M (expense), General and administrative - Balancing increase of 47% to $24.5M (expense), Stock-based Compensation in SGA increase of 54% to $17.3M (expense).
